Electrochemotherapy as a first line treatment in recurrent squamous cell carcinoma of the oral cavity and oropharynx: a randomized controlled trial (ECT-HN)
This research study, called ECT-HN, is exploring a new treatment for mouth and throat cancers that have returned. Specifically, it's looking at cancers of the mouth and the upper part of the throat. The study is comparing a treatment called electrochemotherapy, which uses a drug called bleomycin, against a common treatment combination. The standard treatment involves drugs like cetuximab, platinum-based therapy, and 5-fluorouracil. The main aim is to find out if electrochemotherapy with bleomycin is better at shrinking the cancer. This is an early-stage study (Phase II) meaning it's still investigating how well the new treatment works and if it's safe. It's for adults aged 18 and over, both men and women.
At a glance
What is this study about?
This study, known as ECT-HN, is looking into new ways to treat a type of cancer that affects the mouth and the upper part of the throat. This is specifically for cancers that have come back after previous treatment. The researchers want to see if a treatment called electrochemotherapy, using a drug called bleomycin, works better than a more standard combination of treatments.
Electrochemotherapy is a method where a cancer-fighting drug is given, and then gentle electrical pulses are used to help the drug get into the cancer cells more effectively. In this study, they're comparing this approach with a combination of drugs that doctors commonly use: cetuximab, a platinum-based treatment (like cisplatin or carboplatin), and 5-fluorouracil. The main thing they want to find is which treatment is better at shrinking or getting rid of the cancer.
Beyond simply shrinking the cancer, the study will also look at other important things. This includes how long people live, how long they stay free of the cancer growing again, and how long the treatment's positive effects last. They will also assess how well the treatments control the disease in general and, very importantly, how these treatments affect a person's quality of life. This includes looking at things like pain and bleeding, which can be significant concerns for people with these cancers.
Key takeaways
- This study is testing a new treatment for recurrent mouth and throat cancer.
- It compares electrochemotherapy with a standard drug combination.
- The main goal is to see which treatment shrinks cancer better.
- The study also checks quality of life, pain, and bleeding.
- It's for adults aged 18 and over, both men and women.
- You have the right to leave the study at any time.
Who may be eligible?
To be considered for this study, you must be 18 years old or older. The study is open to both men and women.
Since this study is specifically for certain mouth and throat cancers that have returned, a doctor will need to confirm your specific cancer type and history to make sure it matches what the study is looking for.
There will be other detailed medical checks to ensure the treatment is safe for you and that you meet all the health requirements to participate. Your doctor will discuss all of these with you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have a type of cancer in your mouth or upper throat?
- Has your cancer come back after earlier treatment?
- Are you able to attend regular hospital visits for treatment and check-ups?
What does participation involve?
If you decide to take part in this study, you will be assigned to receive either the electrochemotherapy with bleomycin or the standard combination of treatments (cetuximab + platinum-based therapy + 5-Fluorouracil). You won't be able to choose which treatment you get. Both treatments involve receiving medication.
Throughout the study, you'll have regular hospital visits for assessments. These will include check-ups to see how the treatment is working, blood tests, and scans to monitor your cancer. You'll also be asked to fill out questionnaires about your quality of life, including how you're feeling and if you're experiencing pain or bleeding.
Doctors will follow your progress closely during and after the treatment periods. The total duration of your participation will depend on the treatment course and ongoing follow-up to track your health and the cancer's status.
Potential risks and benefits
Locations (1)
- —UnverifiedItaly
Common questions
What is electrochemotherapy?
It's a way to make cancer drugs work better. A drug is given, and then gentle electrical pulses help it get into cancer cells more easily.
What kind of cancer is this study for?
This study is for certain types of cancer in the mouth (oral cavity) and the upper part of the throat (oropharynx) that have come back after previous treatment.
Will I know which treatment I'm getting?
No, in this type of study, you won't choose or know which treatment group you're in. This helps researchers compare the treatments fairly.
How long will I be in the study?
The length of time you'll be involved varies. It includes the treatment period and follow-up visits to monitor your health over time.
Can I leave the study if I want to?
Yes, you can leave the study at any time without having to give a reason, and it won't affect your regular medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.